[
  {
    "ts": null,
    "headline": "Tariff turbulence deepens uncertainty across US supply chains",
    "summary": "Logistics leaders say shippers are turning to data visibility, transparency and nearshoring in Mexico to navigate rising supply chain costs and uncertainty. The post Tariff turbulence deepens uncertainty across US supply chains appeared first on FreightWaves.",
    "url": "https://finnhub.io/api/news?id=c364d8fd0321b95af9051216b543f31d525995629af84d0dd472032ce73116b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759953303,
      "headline": "Tariff turbulence deepens uncertainty across US supply chains",
      "id": 137028228,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Logistics leaders say shippers are turning to data visibility, transparency and nearshoring in Mexico to navigate rising supply chain costs and uncertainty. The post Tariff turbulence deepens uncertainty across US supply chains appeared first on FreightWaves.",
      "url": "https://finnhub.io/api/news?id=c364d8fd0321b95af9051216b543f31d525995629af84d0dd472032ce73116b2"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
    "summary": "Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index and the Health Car",
    "url": "https://finnhub.io/api/news?id=c77ca0ef10a66503338e84d3b63d022b5d1daab8a42a4c7a3c3b3d98e160fcd1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759952074,
      "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
      "id": 137028229,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index and the Health Car",
      "url": "https://finnhub.io/api/news?id=c77ca0ef10a66503338e84d3b63d022b5d1daab8a42a4c7a3c3b3d98e160fcd1"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Wednesday Afternoon",
    "summary": "Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index adding 0.3% and the Hea",
    "url": "https://finnhub.io/api/news?id=60124b56284cf237076a6a717651fe2a0fbc71f9fbd2d0f46b13cbedfeca337d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759945351,
      "headline": "Sector Update: Health Care Stocks Advance Wednesday Afternoon",
      "id": 137012862,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index adding 0.3% and the Hea",
      "url": "https://finnhub.io/api/news?id=60124b56284cf237076a6a717651fe2a0fbc71f9fbd2d0f46b13cbedfeca337d"
    }
  },
  {
    "ts": null,
    "headline": "Hims Stock, Up 138%: IBD Stock Of The Day Makes Another Breakout Run",
    "summary": "Hims & Hers Health is Wednesday's IBD Stock Of The Day. After returning to the IBD 50, Hims stock is making a second attempt at a breakout.",
    "url": "https://finnhub.io/api/news?id=a1a7de5e80d32e5e218ce52f26eb21e949c18bf0920ed6a60bf0532f9bb105f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759942935,
      "headline": "Hims Stock, Up 138%: IBD Stock Of The Day Makes Another Breakout Run",
      "id": 137012863,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims & Hers Health is Wednesday's IBD Stock Of The Day. After returning to the IBD 50, Hims stock is making a second attempt at a breakout.",
      "url": "https://finnhub.io/api/news?id=a1a7de5e80d32e5e218ce52f26eb21e949c18bf0920ed6a60bf0532f9bb105f4"
    }
  },
  {
    "ts": null,
    "headline": "Guggenheim Maintains Eli Lilly and (LLY) Buy Recommendation",
    "summary": "Guggenheim Maintains Eli Lilly and (LLY) Buy Recommendation",
    "url": "https://finnhub.io/api/news?id=04e0721c1c660f931a70bcb0614817560a031ae0ce2173b5343288e506463633",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759941040,
      "headline": "Guggenheim Maintains Eli Lilly and (LLY) Buy Recommendation",
      "id": 137011912,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=04e0721c1c660f931a70bcb0614817560a031ae0ce2173b5343288e506463633"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly’s Recent $1B India Investment a Game Changer for Its Valuation in 2025?",
    "summary": "If you are watching Eli Lilly stock and wondering whether now is the time to buy, sell, or simply watch from the sidelines, you are not alone. The past few weeks have been a whirlwind, with shares bouncing back by 10.6% just this last week and up an impressive 16.0% over the past month. After a red-hot multi-year streak, including a jaw-dropping 494.5% gain over the last five years, Eli Lilly did cool off a bit this past year, dropping 7.0%. With news breaking that former FDA vaccine chief...",
    "url": "https://finnhub.io/api/news?id=c84227cd9d97ba0ae6f8995a7df629935322d3b6f52d37da2a7abc1c0a248b6f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759936410,
      "headline": "Is Eli Lilly’s Recent $1B India Investment a Game Changer for Its Valuation in 2025?",
      "id": 137012864,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "If you are watching Eli Lilly stock and wondering whether now is the time to buy, sell, or simply watch from the sidelines, you are not alone. The past few weeks have been a whirlwind, with shares bouncing back by 10.6% just this last week and up an impressive 16.0% over the past month. After a red-hot multi-year streak, including a jaw-dropping 494.5% gain over the last five years, Eli Lilly did cool off a bit this past year, dropping 7.0%. With news breaking that former FDA vaccine chief...",
      "url": "https://finnhub.io/api/news?id=c84227cd9d97ba0ae6f8995a7df629935322d3b6f52d37da2a7abc1c0a248b6f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Q3 Results Expected to Meet Estimates as Mounjaro Outperforms, Deutsche Bank Says",
    "summary": "Eli Lilly (LLY) is projected to report Q3 results broadly in line with Wall Street expectations, dri",
    "url": "https://finnhub.io/api/news?id=c39ff451b4abaa8ffa9de2b67c2baa6ebbc772ff6004eda5e5c4ed26c0b02aef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759935591,
      "headline": "Eli Lilly's Q3 Results Expected to Meet Estimates as Mounjaro Outperforms, Deutsche Bank Says",
      "id": 137010887,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) is projected to report Q3 results broadly in line with Wall Street expectations, dri",
      "url": "https://finnhub.io/api/news?id=c39ff451b4abaa8ffa9de2b67c2baa6ebbc772ff6004eda5e5c4ed26c0b02aef"
    }
  },
  {
    "ts": null,
    "headline": "Can BMYs Neuroscience Portfolio Help to Diversify Its Business?",
    "summary": "Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline momentum.",
    "url": "https://finnhub.io/api/news?id=ae4880b418ba9bc7428553f78b9bb77a046643587af3434b8468afc8129c0deb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759935360,
      "headline": "Can BMYs Neuroscience Portfolio Help to Diversify Its Business?",
      "id": 137012865,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline momentum.",
      "url": "https://finnhub.io/api/news?id=ae4880b418ba9bc7428553f78b9bb77a046643587af3434b8468afc8129c0deb"
    }
  },
  {
    "ts": null,
    "headline": "Ex-FDA chief Peter Marks joins Eli Lilly’s infectious disease unit",
    "summary": "Marks is now the second high-ranking former FDA employee Lilly has snapped up in the last month.",
    "url": "https://finnhub.io/api/news?id=ea30b16ad34d1e319c4b872caf31970e01a99cda47f80648bc4cfc1481ab98d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759934634,
      "headline": "Ex-FDA chief Peter Marks joins Eli Lilly’s infectious disease unit",
      "id": 137010888,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Marks is now the second high-ranking former FDA employee Lilly has snapped up in the last month.",
      "url": "https://finnhub.io/api/news?id=ea30b16ad34d1e319c4b872caf31970e01a99cda47f80648bc4cfc1481ab98d3"
    }
  },
  {
    "ts": null,
    "headline": "Guggenheim Reaffirms Its Buy Rating on Eli Lilly & Company (LLY) with Price Target of $875",
    "summary": "Eli Lilly & Company (NYSE:LLY) is one of the 10 Best Non-Tech Stocks to Buy According to Reddit, supported by hedge fund interest. Eli Lilly & Company (NYSE:LLY) gained attention on September 29 when Guggenheim reaffirmed its Buy rating with a price target of $875. The analyst noted that there was strong demand for tirzepatide […]",
    "url": "https://finnhub.io/api/news?id=0272759f7f6cb4cda334d41199007bf93db25abf1895a1cadb577f85b98d4775",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759932171,
      "headline": "Guggenheim Reaffirms Its Buy Rating on Eli Lilly & Company (LLY) with Price Target of $875",
      "id": 137010889,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly & Company (NYSE:LLY) is one of the 10 Best Non-Tech Stocks to Buy According to Reddit, supported by hedge fund interest. Eli Lilly & Company (NYSE:LLY) gained attention on September 29 when Guggenheim reaffirmed its Buy rating with a price target of $875. The analyst noted that there was strong demand for tirzepatide […]",
      "url": "https://finnhub.io/api/news?id=0272759f7f6cb4cda334d41199007bf93db25abf1895a1cadb577f85b98d4775"
    }
  },
  {
    "ts": null,
    "headline": "HealthTap Expands Access to Primary Care-Driven Diabetes Treatment Through LillyDirect®",
    "summary": "SUNNYVALE, Calif., October 08, 2025--HealthTap, a leading virtual healthcare provider delivering accessible, high-quality virtual primary care, today announced it will be listed as the latest independent care provider option on Eli Lilly and Company’s digital healthcare platform, LillyDirect® , expanding access to primary care-driven diabetes management. With this news, HealthTap becomes the first primary care telehealth practice accessible via LillyDirect®.",
    "url": "https://finnhub.io/api/news?id=83d7fc58585d717e6111e73fb86b9589920696e59717e1ae9e29c1181dc8b251",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759924800,
      "headline": "HealthTap Expands Access to Primary Care-Driven Diabetes Treatment Through LillyDirect®",
      "id": 137009992,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "SUNNYVALE, Calif., October 08, 2025--HealthTap, a leading virtual healthcare provider delivering accessible, high-quality virtual primary care, today announced it will be listed as the latest independent care provider option on Eli Lilly and Company’s digital healthcare platform, LillyDirect® , expanding access to primary care-driven diabetes management. With this news, HealthTap becomes the first primary care telehealth practice accessible via LillyDirect®.",
      "url": "https://finnhub.io/api/news?id=83d7fc58585d717e6111e73fb86b9589920696e59717e1ae9e29c1181dc8b251"
    }
  },
  {
    "ts": null,
    "headline": "These 2 AI Stocks Could Surpass Oracle in Market Cap by 2030",
    "summary": "Investors should buy stakes in AI-powered stocks with scalable, asset-light business models.",
    "url": "https://finnhub.io/api/news?id=846f9049c6e736769d45e7ee03987a2588d07eeb4d2d9eecafe833a58e5491ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759919460,
      "headline": "These 2 AI Stocks Could Surpass Oracle in Market Cap by 2030",
      "id": 137009993,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investors should buy stakes in AI-powered stocks with scalable, asset-light business models.",
      "url": "https://finnhub.io/api/news?id=846f9049c6e736769d45e7ee03987a2588d07eeb4d2d9eecafe833a58e5491ac"
    }
  },
  {
    "ts": null,
    "headline": "Clustermarket Rebrands to Calira and Secures Industry Veteran to Capitalise on Demand for Optimised R&D Lab Operations",
    "summary": "LONDON, October 08, 2025--Clustermarket, the lab equipment scheduling platform, has today announced it is rebranding to Calira and welcoming non-executive director and investor Edmund Wilson, co-founder and former CEO of Titian Software (now Cenevo), to capitalise on increasing enterprise demand for optimising lab operations.",
    "url": "https://finnhub.io/api/news?id=29788823be757dd4838d896daad59de0b854847de1b905b10d9e03647d780af5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759906800,
      "headline": "Clustermarket Rebrands to Calira and Secures Industry Veteran to Capitalise on Demand for Optimised R&D Lab Operations",
      "id": 137009136,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LONDON, October 08, 2025--Clustermarket, the lab equipment scheduling platform, has today announced it is rebranding to Calira and welcoming non-executive director and investor Edmund Wilson, co-founder and former CEO of Titian Software (now Cenevo), to capitalise on increasing enterprise demand for optimising lab operations.",
      "url": "https://finnhub.io/api/news?id=29788823be757dd4838d896daad59de0b854847de1b905b10d9e03647d780af5"
    }
  }
]